Pasar al contenido principal

TERAPIA GENICA Y OTRAS TERAPIAS INNOVADORAS PARA EL TRATAMIENTO DE LOS SINDROMES CONGENITOS CON FALLO DE MEDULA OSEA

SAF2015-68073-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario CENTRO DE INVESTIGACION ENERGETICA MEDIOAMBIENTAL Y TECNOLOGICA (CIEMAT)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells.

  • Pintado-Berninches, Laura
  • Fernandez-Varas, Beatriz
  • Benitez-Buelga, Carlos
  • Manguan-Garcia, Cristina
  • Serrano-Benitez, Almudena
  • Iarriccio, Laura
  • Carrillo, Jaime
  • Guenechea, Guillermo
  • Egusquiaguirre, Susana P
  • Pedraz, Jose-Luis
  • Hernández, Rosa M
  • Igartua, Manoli
  • Arias-Salgado, Elena G
  • Cortes-Ledesma, Felipe
  • Sastre, Leandro
  • Perona, Rosario
  • Pintado-Berninches, Laura
  • Fernandez-Varas, Beatriz
  • Benitez-Buelga, Carlos
  • Manguan-Garcia, Cristina
  • Serrano-Benitez, Almudena
  • Iarriccio, Laura
  • Carrillo, Jaime
  • Guenechea, Guillermo
  • Egusquiaguirre, Susana P
  • Pedraz, Jose-Luis
  • Hernández, Rosa M
  • Igartua, Manoli
  • Arias-Salgado, Elena G
  • Sastre, Leandro
  • Perona, Rosario
Ataxia telangiectasia (AT) is a genetic disease caused by mutations in the ATM gene but the mechanisms underlying AT are not completely understood. Key functions of the ATM protein are to sense and regulate cellular redox status and to transduce DNA double-strand break signals to downstream effectors. ATM-deficient cells show increased ROS accumulation, activation of p38 protein kinase, and increased levels of DNA damage. GSE24.2 peptide and a short derivative GSE4 peptide corresponding to an internal domain of Dyskerin have proved to induce telomerase activity, decrease oxidative stress, and protect from DNA damage in dyskeratosis congenita (DC) cells. We have found that expression of GSE24.2 and GSE4 in human AT fibroblast is able to decrease DNA damage, detected by γ-H2A.X and 53BP1 foci. However, GSE24.2/GSE4 expression does not improve double-strand break signaling and repair caused by the lack of ATM activity. In contrast, they cause a decrease in 8-oxoguanine and OGG1-derived lesions, particularly at telomeres and mitochondrial DNA, as well as in reactive oxygen species, in parallel with increased expression of SOD1. These cells also showed lower levels of IL6 and decreased p38 phosphorylation, decreased senescence and increased ability to divide for longer times. Additionally, these cells are more resistant to treatment with H0 and the radiomimetic-drug bleomycin. Finally, we found shorter telomere length (TL) in AT cells, lower levels of TERT expression, and telomerase activity that were also partially reverted by GSE4. These observations suggest that GSE4 may be considered as a new therapy for the treatment of AT that counteracts the cellular effects of high ROS levels generated in AT cells and in addition increases telomerase activity contributing to increased cell proliferation.
Repisalud
Publicación Artículo científico (JournalArticle)

NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.

  • Román-Rodríguez, Francisco José
  • Ugalde, Laura
  • Álvarez, Lara
  • Díez, Begoña
  • Ramírez, María José
  • Risueño, Cristina
  • Cortón, Marta
  • Bogliolo, Massimo
  • Bernal, Sara
  • March, Francesca
  • Ayuso, Carmen
  • Hanenberg, Helmut
  • Sevilla, Julián
  • Rodriguez Perales, Sandra
  • Torres-Ruiz, Raul
  • Surrallés, Jordi
  • Bueren, Juan Antonio
  • Río, Paula
Non-homologous end-joining (NHEJ) is the preferred mechanism used by hematopoietic stem cells (HSCs) to repair double-stranded DNA breaks and is particularly increased in cells deficient in the Fanconi anemia (FA) pathway. Here, we show feasible correction of compromised functional phenotypes in hematopoietic cells from multiple FA complementation groups, including FA-A, FA-C, FA-D1, and FA-D2. NHEJ-mediated repair of targeted CRISPR-Cas9-induced DNA breaks generated compensatory insertions and deletions that restore the coding frame of the mutated gene. NHEJ-mediated editing efficacy was initially verified in FA lymphoblastic cell lines and then in primary FA patient-derived CD34 cells, which showed marked proliferative advantage and phenotypic correction both in vitro and after transplantation. Importantly, and in contrast to homologous directed repair, NHEJ efficiently targeted primitive human HSCs, indicating that NHEJ editing approaches may constitute a sound alternative for editing self-renewing human HSCs and consequently for treatment of FA and other monogenic diseases affecting the hematopoietic system.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Generation and potential applications of an X-linked dyskeratosis congenita model in human hematopoietic stem cells

  • Carrascoso-Rubio, C.
  • Zittersteijn, H. A.
  • Pintado-Berninches, Laura
  • Fernández-Varas, Beatriz
  • Lozano, M. L.
  • Manguan-García, Cristina
  • Sastre, Leandro
  • Bueren-Calabuig, Juan A.
  • Perona Abellón, Rosario
  • Guenechea, Guillermo
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., This work was supported by grants from “Ministerio de Economía, Comercio y Competitividad y Fondo Europeo de Desarrollo Regional (FEDER)” (SAF2015-68073-R) and CIBERER is an initiative of the “Instituto de Salud Carlos III” and “Fondo Europeo de Desarrollo Regional (FEDER)”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GSE4 peptide suppresses oxidative and telomere deficiencies in Ataxia Telangiectasia patient cells

  • Pintado-Berninches, Laura
  • Fernández-Varas, Beatriz
  • Benitez-Buelga, Carlos
  • Manguan-García, Cristina
  • Serrano-Benítez, Almudena
  • Iarriccio, Laura
  • Carrillo, Jaime
  • Guenechea, Guillermo
  • Egusquiaguirre, Susana P.
  • Pedraz, José Luís
  • Hernández, Rosa M.
  • Igartua, Manuela
  • Arias-Salgado, Elena G.
  • Cortés-Ledesma, Felipe
  • Sastre, Leandro
  • Perona Abellón, Rosario
Ataxia telangiectasia (AT) is a genetic disease caused by mutations in the ATM gene but the mechanisms underlying AT are not completely understood. Key functions of the ATM protein are to sense and regulate cellular redox status and to transduce DNA double-strand break signals to downstream effectors. ATM-deficient cells show increased ROS accumulation, activation of p38 protein kinase, and increased levels of DNA damage. GSE24.2 peptide and a short derivative GSE4 peptide corresponding to an internal domain of Dyskerin have proved to induce telomerase activity, decrease oxidative stress, and protect from DNA damage in dyskeratosis congenita (DC) cells. We have found that expression of GSE24.2 and GSE4 in human AT fibroblast is able to decrease DNA damage, detected by γ-H2A.X and 53BP1 foci. However, GSE24.2/GSE4 expression does not improve double-strand break signaling and repair caused by the lack of ATM activity. In contrast, they cause a decrease in 8-oxoguanine and OGG1-derived lesions, particularly at telomeres and mitochondrial DNA, as well as in reactive oxygen species, in parallel with increased expression of SOD1. These cells also showed lower levels of IL6 and decreased p38 phosphorylation, decreased senescence and increased ability to divide for longer times. Additionally, these cells are more resistant to treatment with H202 and the radiomimetic-drug bleomycin. Finally, we found shorter telomere length (TL) in AT cells, lower levels of TERT expression, and telomerase activity that were also partially reverted by GSE4. These observations suggest that GSE4 may be considered as a new therapy for the treatment of AT that counteracts the cellular effects of high ROS levels generated in AT cells and in addition increases telomerase activity contributing to increased cell proliferation., RP laboratory is funded by grant P14-01495 and P17-01401 (Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain supported by FEDER funds) and CIBER 576/805_ER16PE06P2016 supported by FEDER funds. GG grant “Ministerio de Economía, Comercio y Competitividad y Fondo Europeo de Desarrollo Regional (FEDER)” (SAF2015-68073-R). CM-G is granted by the CIBERER. Work in FC-L laboratory is funded with grants from the Spanish Government (SAF2014-55532-R, Ministerio de Economía, Industria y Competitividad), the regional Andalusian Government (CVI-7948), the Fundación Ramón Areces (XVII Convocatoria Ciencias de la Vida y Materia), the European Research Council (ERC-CoG-2014-647359), and with a Predoctoral Fellowship from AEFAT (Asociación Española Familia Ataxia Telangiectasia) to AS-B. BER OGG1 was kindly provided by Professor Thomas Helleday’s Lab, Karolinska Institutet, Sweden.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation of dyskeratosis congenita-like hematopoietic stem cells through the stable inhibition of DKC1

  • Carrascoso-Rubio, C.
  • Zittersteijn, H. A.
  • Pintado-Berninches, Laura
  • Fernández-Varas, Beatriz
  • Lozano, M. L.
  • Manguan-García, Cristina
  • Sastre, Leandro
  • Bueren-Calabuig, Juan A.
  • Perona Abellón, Rosario
  • Guenechea, Guillermo
© The Author(s)., Dyskeratosis congenita (DC) is a rare telomere biology disorder, which results in different clinical manifestations, including severe bone marrow failure. To date, the only curative treatment for the bone marrow failure in DC patients is allogeneic hematopoietic stem cell transplantation. However, due to the toxicity associated to this treatment, improved therapies are recommended for DC patients. Here, we aimed at generating DC-like human hematopoietic stem cells in which the efficacy of innovative therapies could be investigated. Because X-linked DC is the most frequent form of the disease and is associated with an impaired expression of DKC1, we have generated DC-like hematopoietic stem cells based on the stable knock-down of DKC1 in human CD34+ cells with lentiviral vectors encoding for DKC1 short hairpin RNAs. At a molecular level, DKC1-interfered CD34+ cells showed a decreased expression of TERC, as well as a diminished telomerase activity and increased DNA damage, cell senescence, and apoptosis. Moreover, DKC1-interfered human CD34+ cells showed defective clonogenic ability and were incapable of repopulating the hematopoiesis of immunodeficient NSG mice. The development of DC-like hematopoietic stem cells will facilitate the understanding of the molecular and cellular basis of this inherited bone marrow failure syndrome and will serve as a platform to evaluate the efficacy of new hematopoietic therapies for DC., This work was supported by grants from the “Ministerio de Economía, Comercio y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER)” (SAF2015-68073-R) and from the “Ministerio de Ciencia, Innovación y Universidades and Fondo Europeo de Desarrollo Regional (FEDER)” (RTI2018-097125-B-I00) and P17-01401 from “Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (FIS-ISCIII)”. The authors also thank the Fundación Botín for promoting translational research at the Hematopoietic Innovative Therapies Division of the CIEMAT. CIBERER is an initiative of the “Instituto de Salud Carlos III” and “FEDER”. CCR was supported by an FPI grant from the Universidad Autónoma de Madrid (UAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage

  • Pintado-Berninches, Laura
  • Montes-Worboys, Ana
  • Manguan-García, Cristina
  • Arias-Salgado, Elena G.
  • Serrano, Adela
  • Fernández-Varas, Beatriz
  • Guerrero-López, Rosa
  • Iarriccio, Laura
  • Planas-Cerezales, Lurdes
  • Guenechea, Guillermo
  • Egusquiaguirre, Susana P.
  • Hernández, Rosa M.
  • Igartua, Manuela
  • Pedraz, José Luís
  • Cortijo, Julio
  • Sastre, Leandro
  • Molina-Molina, María
  • Perona Abellón, Rosario
© 2021 The Authors., Idiopathic pulmonary fibrosis is a lethal lung fibrotic disease, associated with aging with a mean survival of 2-5 years and no curative treatment. The GSE4 peptide is able to rescue cells from senescence, DNA and oxidative damage, inflammation, and induces telomerase activity. Here, we investigated the protective effect of GSE4 expression in vitro in rat alveolar epithelial cells (AECs), and in vivo in a bleomycin model of lung fibrosis. Bleomycin-injured rat AECs, expressing GSE4 or treated with GSE4-PLGA/PEI nanoparticles showed an increase of telomerase activity, decreased DNA damage, and decreased expression of IL6 and cleaved-caspase 3. In addition, these cells showed an inhibition in expression of fibrotic markers induced by TGF-β such as collagen-I and III among others. Furthermore, treatment with GSE4-PLGA/PEI nanoparticles in a rat model of bleomycin-induced fibrosis, increased telomerase activity and decreased DNA damage in proSP-C cells. Both in preventive and therapeutic protocols GSE4-PLGA/PEI nanoparticles prevented and attenuated lung damage monitored by SPECT-CT and inhibited collagen deposition. Lungs of rats treated with bleomycin and GSE4-PLGA/PEI nanoparticles showed reduced expression of α-SMA and pro-inflammatory cytokines, increased number of pro-SPC-multicellular structures and increased DNA synthesis in proSP-C cells, indicating therapeutic efficacy of GSE4-nanoparticles in experimental lung fibrosis and a possible curative treatment for lung fibrotic patients., R.P laboratory was funded by grants P17-01401 (Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain supported by FEDER funds), CIBER 576/805_ER16PE06P2016 and MINECO from the Spanish Government (INNPACTO, IPT-2012-0674-090000). M.M-M. laboratory was funded by Instituto de Salud Carlos III PI18/00367, supported by FEDER (Fondos Europeos de Desarrollo Regional (a way to build Europe)), JC received funds from MINECO CICYT SAF2014-55322-P, and GG laboratory was funded by grant SAF2015-68073-R (MINECO/FEDER) supported by FEDER funds. C.MG and R G-L are granted by the CIBERER.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

  • Sevilla, Julián|||0000-0002-6852-1860
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Río, Paula
  • Sánchez Domínguez, Rebeca
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Gálvez, Eva
  • Merino, Eva
  • Sebastián, Elena
  • Azqueta, Carmen
  • Casado, José A.|||0000-0003-2479-1508
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Román-Rodríguez, Francisco J.
  • Giménez, Yari|||0000-0002-8936-0007
  • Larcher, Lise
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hladun, Raquel|||0000-0002-3191-1750
  • Castillo, Ana
  • Soulier, Jean|||0000-0002-8734-5356
  • Querol, Sergi|||0000-0002-1105-8633
  • Fernández, Jesús
  • Schwartz, Jonathan|||0000-0002-2211-4151
  • García de Andoín, Nagore|||0000-0003-2660-2600
  • López, Ricardo
  • Català, Albert|||0000-0003-0133-1752
  • Surralles, Jordi|||0000-0002-4041-7519
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Bueren, Juan|||0000-0002-3228-7013
Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21.8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4.27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1.1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TALEN mediated gene editing in a mouse model of Fanconi anemia

  • Pino-Barrio, Maria José
  • Giménez, Yari|||0000-0002-8936-0007
  • Villanueva, Mariela
  • Hildenbeutel, Marcus
  • Sánchez Domínguez, Rebeca
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Surralles, Jordi|||0000-0002-4041-7519
  • Río, Paula
  • Cathomen, Toni|||0000-0002-7757-4630
  • Mussolino, Claudio
  • Bueren, Juan|||0000-0002-3228-7013
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
The promising ability to genetically modify hematopoietic stem and progenitor cells by precise gene editing remains challenging due to their sensitivity to in vitro manipulations and poor efficiencies of homologous recombination. This study represents the first evidence of implementing a gene editing strategy in a murine safe harbor locus site that phenotypically corrects primary cells from a mouse model of Fanconi anemia A. By means of the co-delivery of transcription activator-like effector nucleases and a donor therapeutic FANCA template to the Mbs85 locus, we achieved efficient gene targeting (23%) in mFA-A fibroblasts. This resulted in the phenotypic correction of these cells, as revealed by the reduced sensitivity of these cells to mitomycin C. Moreover, robust evidence of targeted integration was observed in murine wild type and FA-A hematopoietic progenitor cells, reaching mean targeted integration values of 21% and 16% respectively, that were associated with the phenotypic correction of these cells. Overall, our results demonstrate the feasibility of implementing a therapeutic targeted integration strategy into the m Mbs85 locus, ortholog to the well-validated hAAVS1, constituting the first study of gene editing in mHSC with TALEN, that sets the basis for the use of a new safe harbor locus in mice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Casado, José A.|||0000-0003-2479-1508
  • Valeri, A.
  • Sánchez Domínguez, Rebeca
  • Vela, Paula
  • Lopez, A.
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Hanenberg, H.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Segovia, J. C.
  • Minguillon, J.
  • Surralles, Jordi|||0000-0002-4041-7519
  • De Heredia, C.D.
  • Sevilla, J.
  • Rio, P.
  • Bueren, Juan|||0000-0002-3228-7013
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.